Skip Navigation


Annals of Oncology Advance Access originally published online on December 1, 2005
Annals of Oncology 2006 17(3):507-514; doi:10.1093/annonc/mdj092
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
17/3/507    most recent
mdj092v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lalami, Y.
Right arrow Articles by Klastersky, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lalami, Y.
Right arrow Articles by Klastersky, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2005 European Society for Medical Oncology

Can we predict the duration of chemotherapy-induced neutropenia in febrile neutropenic patients, focusing on regimen-specific risk factors? A retrospective analysis

Y. Lalami1,*, M. Paesmans2, F. Muanza2, M. Barette2, B. Plehiers1, L. Dubreucq2, A. Georgala1 and J. Klastersky1

1 Department of Médecine Interne and Laboratoire d'Investigations Cliniques H-J Tagnon, Centre des Tumeurs de l'Université Libre de Bruxelles; 2 Jules Bordet Institut, Data Centre, Rue Héger Bordet 1, 1000 Brussels, Belgium

* Correspondance to: Dr Y. Lalami, Institut Jules Bordet, Rue Héger Bordet 1, 1000 Bruxelles, Belgium. Tel: +322/541-32-35; Fax: +322/541-33-12; E-mail: yassine.lalami{at}bordet.be

Background: The aim of the study was to elaborate a predictive model for the duration of chemotherapy-induced neutropenia (CIN) allowing the identification of patients with a higher risk of complications, especially complicated febrile neutropenia, who might benefit from preventive measures.

Patients and methods: A score ranging from 0 to 4 on the basis of expected CIN was attributed to each cytotoxic agent given as part of chemotherapy treatment in solid tumours for patients with febrile neutropenia (FN). The individual scores were combined into several overall scores.

Results: A total of 203 patients with FN were eligible for this retrospective analysis. We were able to identify two groups of patients with statistically different neutropenia durations with median durations until hematological recovery of ANC ≥0.5 and ≥1.0 x 109/l, being respectively 6 versus 4 days (P = 0.03) and 8 versus 6 days (P = 0.01).

Conclusions: The duration of neutropenia is directly influenced by the aggressiveness of the chemotherapy regimen. In this retrospective study, we were able to identify a group of patients who needed two more additional days to recover from grade 3 and grade 4 neutropenia, based on the degree of aggressiveness of the cytotoxic agents used.

Key words: chemotherapy, neutropenia, febrile neutropenia, duration of neutropenia


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Moreau, J. Klastersky, A. Schwarzbold, F. Muanza, A. Georgala, M. Aoun, A. Loizidou, M. Barette, S. Costantini, M. Delmelle, et al.
A general chemotherapy myelotoxicity score to predict febrile neutropenia in hematological malignancies
Ann. Onc., March 1, 2009; 20(3): 513 - 519.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.